View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAbcam 将来の成長Future 基準チェック /46主要情報36.7%収益成長率44.66%EPS成長率Biotechs 収益成長15.7%収益成長率13.2%将来の株主資本利益率10.65%アナリストカバレッジGood最終更新日n/a今後の成長に関する最新情報Major Estimate Revision • Mar 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from UK£0.20 to UK£0.16 per share. Revenue forecast steady at UK£378.0m. Net income forecast to grow 708% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target down from UK£15.70 to UK£15.27. Share price rose 8.4% to UK£13.59 over the past week.Major Estimate Revision • Mar 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.07 to UK£0.06 per share. Revenue forecast steady at UK£313.9m. Net income forecast to grow 75% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target of UK£15.71 unchanged from last update. Share price fell 4.9% to UK£11.71 over the past week.Major Estimate Revision • Jan 07Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.10 to UK£0.09 per share. Revenue forecast steady at UK£317.0m. Net income forecast to grow 147% next year vs 7.0% growth forecast for Biotechs industry in the United Kingdom. Consensus price target up from UK£14.89 to UK£15.21. Share price fell 12% to UK£15.28 over the past week.Price Target Changed • Feb 22Price target raised to UK£14.14Up from UK£13.09, the current price target is an average from 12 analysts. The new target price is 16% below the current share price of UK£16.76. As of last close, the stock is up 37% over the past year.Major Estimate Revision • Jan 19Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate increased from UK£0.11 to UK£0.13. Revenue estimate for the same period was approximately flat at UK£298.0m. Net income is expected to grow by 139% next year compared to 4.2% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£13.09 to UK£14.00. Share price is up 2.8% to UK£17.13 over the past week.Price Target Changed • Jan 15Price target raised to UK£14.00Up from UK£13.06, the current price target is an average from 12 analysts. The new target price is 18% below the current share price of UK£17.04. As of last close, the stock is up 22% over the past year.すべての更新を表示Recent updates分析記事 • Jun 24Abcam plc (LON:ABC) Shares Could Be 28% Below Their Intrinsic Value EstimateIn this article we are going to estimate the intrinsic value of Abcam plc ( LON:ABC ) by projecting its future cash...分析記事 • May 01Is Abcam (LON:ABC) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Buying Opportunity • Apr 21Now 22% undervaluedOver the last 90 days, the stock is up 4.2%. The fair value is estimated to be UK£17.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 35% per annum over the same time period.Recent Insider Transactions • Apr 09Key Executive recently bought UK£67k worth of stockOn the 4th of April, Peter Allen bought around 5k shares on-market at roughly UK£14.36 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.Major Estimate Revision • Mar 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from UK£0.20 to UK£0.16 per share. Revenue forecast steady at UK£378.0m. Net income forecast to grow 708% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target down from UK£15.70 to UK£15.27. Share price rose 8.4% to UK£13.59 over the past week.Reported Earnings • Mar 15Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: EPS: UK£0.019 (up from UK£0.009 loss in FY 2020). Revenue: UK£315.4m (up 17% from FY 2020). Net income: UK£4.40m (up UK£6.30m from FY 2020). Profit margin: 1.4% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 66%. Over the next year, revenue is forecast to grow 19%, compared to a 20% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.Major Estimate Revision • Mar 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.07 to UK£0.06 per share. Revenue forecast steady at UK£313.9m. Net income forecast to grow 75% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target of UK£15.71 unchanged from last update. Share price fell 4.9% to UK£11.71 over the past week.分析記事 • Mar 08Is There An Opportunity With Abcam plc's (LON:ABC) 39% Undervaluation?Today we will run through one way of estimating the intrinsic value of Abcam plc ( LON:ABC ) by estimating the...Major Estimate Revision • Jan 07Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.10 to UK£0.09 per share. Revenue forecast steady at UK£317.0m. Net income forecast to grow 147% next year vs 7.0% growth forecast for Biotechs industry in the United Kingdom. Consensus price target up from UK£14.89 to UK£15.21. Share price fell 12% to UK£15.28 over the past week.分析記事 • Nov 22Calculating The Fair Value Of Abcam plc (LON:ABC)Does the November share price for Abcam plc ( LON:ABC ) reflect what it's really worth? Today, we will estimate the...Recent Insider Transactions Derivative • Nov 12CEO & Executive Director exercised options and sold UK£926k worth of stockOn the 8th of November, Alan Hirzel exercised options to acquire 55k shares at no cost and sold these for an average price of UK£16.89 per share. This trade did not impact their existing holding. For the year to June 2020, Alan's total compensation was 39% salary and 61% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Alan's direct individual holding has increased from 214.87k shares to 221.76k. Company insiders have collectively sold UK£1.1m more than they bought, via options and on-market transactions in the last 12 months.Recent Insider Transactions • Sep 26CEO & Executive Director recently sold UK£94k worth of stockOn the 23rd of September, Alan Hirzel sold around 6k shares on-market at roughly UK£15.36 per share. This was the largest sale by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.Reported Earnings • Sep 15Full year 2021 earnings released: EPS UK£0.073 (vs UK£0.06 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£297.7m (up 14% from FY 2020). Net income: UK£16.2m (up 30% from FY 2020). Profit margin: 5.4% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.分析記事 • Jun 25Shareholders Will Probably Be Cautious Of Increasing Abcam plc's (LON:ABC) CEO Compensation At The MomentThe anaemic share price growth at Abcam plc ( LON:ABC ) over the past few years has probably not impressed shareholders...Executive Departure • May 27Senior Independent Director has left the companyOn the 19th of May, Louise A. V. Patten's tenure as Senior Independent Director ended after 6.5 years in the role. As of March 2021, Louise A. V. personally held 54.84k shares (UK£763k worth at the time). Louise A. V. is the only executive to leave the company over the last 12 months.Reported Earnings • Mar 10First half 2021 earnings released: EPS UK£0.053 (vs UK£0.13 in 1H 2020)The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£147.5m (up 6.7% from 1H 2020). Net income: UK£11.7m (down 55% from 1H 2020). Profit margin: 7.9% (down from 19% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.Analyst Estimate Surprise Post Earnings • Mar 09Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 18%, compared to a 44% growth forecast for the Biotechs industry in the United Kingdom.Price Target Changed • Feb 22Price target raised to UK£14.14Up from UK£13.09, the current price target is an average from 12 analysts. The new target price is 16% below the current share price of UK£16.76. As of last close, the stock is up 37% over the past year.分析記事 • Feb 09Here's What We Think About Abcam's (LON:ABC) CEO PayAlan Hirzel has been the CEO of Abcam plc ( LON:ABC ) since 2014, and this article will examine the executive's...Recent Insider Transactions Derivative • Feb 06CFO & Director exercised options and sold UK£73k worth of stockOn the 3rd of February, Michael Baldock exercised options to acquire 4k shares at no cost and sold these for an average price of UK£16.40 per share. This trade did not impact their existing holding. As of today, Michael currently holds no shares directly. Company insiders have collectively sold UK£260k more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Jan 19Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate increased from UK£0.11 to UK£0.13. Revenue estimate for the same period was approximately flat at UK£298.0m. Net income is expected to grow by 139% next year compared to 4.2% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£13.09 to UK£14.00. Share price is up 2.8% to UK£17.13 over the past week.分析記事 • Jan 17Abcam plc's (LON:ABC) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?Most readers would already be aware that Abcam's (LON:ABC) stock increased significantly by 30% over the past three...Price Target Changed • Jan 15Price target raised to UK£14.00Up from UK£13.06, the current price target is an average from 12 analysts. The new target price is 18% below the current share price of UK£17.04. As of last close, the stock is up 22% over the past year.Is New 90 Day High Low • Jan 13New 90-day high: UK£16.66The company is up 29% from its price of UK£12.92 on 14 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£7.26 per share.分析記事 • Dec 27Shareholders Are Thrilled That The Abcam (LON:ABC) Share Price Increased 124%When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...Major Estimate Revision • Dec 19Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate was lowered from UK£0.14 to UK£0.11. No change was made to the revenue estimate which at the last update was UK£297.2m. Net income is expected to grow by 94% next year compared to 4.1% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£12.65 to UK£12.96. Share price is up 1.6% to UK£14.38 over the past week.分析記事 • Dec 06Are Abcam's (LON:ABC) Statutory Earnings A Good Reflection Of Its Earnings Potential?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...Recent Insider Transactions Derivative • Nov 05CEO & Executive Director exercised options and sold UK£291k worth of stockOn the 3rd of November, Alan Hirzel exercised options to acquire 19.43k shares at no cost and sold these for an average price of UK£14.99 per share. This trade did not impact their existing holding. For the year to June 2020, Alan's total compensation was 39% salary and 61% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since December 2019, Alan's direct individual holding has increased from 151.13k shares to 180.26k. Company insiders have collectively sold UK£16m more than they bought, via options and on-market transactions in the last 12 months.Major Estimate Revision • Oct 24Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate was lowered from UK£0.14 to UK£0.13. Revenue estimate was approximately flat at UK£296.9m. Net income is expected to grow by 123% next year compared to 11% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target was lowered from UK£12.67 to UK£12.37. Share price is up 9.6% to UK£14.41 over the past week.Is New 90 Day High Low • Oct 22New 90-day high: UK£14.25The company is up 8.0% from its price of UK£13.21 on 24 July 2020. The British market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£5.10 per share.Major Estimate Revision • Oct 09Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate was lowered from UK£0.16 to UK£0.14. Revenue estimate was approximately flat at UK£298.3m. Net income is expected to grow by 145% next year compared to 9.5% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target was lowered from UK£12.84 to UK£12.67. Share price stayed mostly flat at UK£12.13 over the past week.Reported Earnings • Oct 04Full year earnings released - EPS UK£0.06Over the last 12 months the company has reported total profits of UK£12.5m, down 72% from the prior year. Total revenue was UK£260.0m over the last 12 months, largely unchanged from the prior year. Profit margins were 4.8%, which is lower than the 17% margin from last year. The decrease in margin was driven by higher expenses.Major Estimate Revision • Sep 21Analysts update estimatesThe 2021 consensus revenue estimate increased from UK£298.3m to UK£301.4m. Earnings per share (EPS) estimate was lowered from UK£0.19 to UK£0.15 for the same period. Net income is expected to grow by 161% next year compared to 12% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£12.62 to UK£12.89. Share price is down by 9.9% to UK£12.45 over the past week.業績と収益の成長予測AIM:ABC - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202450078120155712/31/20234486174133912/31/202238938379296/30/202235071255N/A3/31/20223336759N/A12/31/20213154363N/A6/30/2021298161572N/A3/31/202128471465N/A12/31/2020295261867N/A9/30/202026552060N/A6/30/2020260132763N/A3/31/2020267273167N/A12/31/2019273433673N/A9/30/2019267443372N/A6/30/2019260443069N/A3/31/2019253512569N/A12/31/2018245582167N/A9/30/2018239602365N/A6/30/2018233622663N/A3/31/2018230593564N/A12/31/2017227554464N/A9/30/2017222494665N/A6/30/2017217424766N/A3/31/2017206414564N/A12/31/2016196404362N/A9/30/2016184393755N/A6/30/2016172373247N/A3/31/201616437N/A45N/A12/31/201515637N/A43N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: ABCの予測収益成長率 (年間36.7% ) は 貯蓄率 ( 1% ) を上回っています。収益対市場: ABCの収益 ( 36.7% ) はUK市場 ( 11.5% ) よりも速いペースで成長すると予測されています。高成長収益: ABCの収益は今後 3 年間で 大幅に 増加すると予想されています。収益対市場: ABCの収益 ( 13.2% ) UK市場 ( 4.5% ) よりも速いペースで成長すると予測されています。高い収益成長: ABCの収益 ( 13.2% ) 20%よりも低い成長が予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: ABCの 自己資本利益率 は、3年後には低くなると予測されています ( 10.7 %)。成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2022/12/15 20:43終値2022/12/13 00:00収益2022/06/30年間収益2021/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Abcam plc 9 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。18 アナリスト機関Xian DengBerenbergMichael RyskinBofA Global ResearchPaul KnightBrean Capital Historical (Janney Montgomery)15 その他のアナリストを表示
Major Estimate Revision • Mar 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from UK£0.20 to UK£0.16 per share. Revenue forecast steady at UK£378.0m. Net income forecast to grow 708% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target down from UK£15.70 to UK£15.27. Share price rose 8.4% to UK£13.59 over the past week.
Major Estimate Revision • Mar 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.07 to UK£0.06 per share. Revenue forecast steady at UK£313.9m. Net income forecast to grow 75% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target of UK£15.71 unchanged from last update. Share price fell 4.9% to UK£11.71 over the past week.
Major Estimate Revision • Jan 07Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.10 to UK£0.09 per share. Revenue forecast steady at UK£317.0m. Net income forecast to grow 147% next year vs 7.0% growth forecast for Biotechs industry in the United Kingdom. Consensus price target up from UK£14.89 to UK£15.21. Share price fell 12% to UK£15.28 over the past week.
Price Target Changed • Feb 22Price target raised to UK£14.14Up from UK£13.09, the current price target is an average from 12 analysts. The new target price is 16% below the current share price of UK£16.76. As of last close, the stock is up 37% over the past year.
Major Estimate Revision • Jan 19Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate increased from UK£0.11 to UK£0.13. Revenue estimate for the same period was approximately flat at UK£298.0m. Net income is expected to grow by 139% next year compared to 4.2% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£13.09 to UK£14.00. Share price is up 2.8% to UK£17.13 over the past week.
Price Target Changed • Jan 15Price target raised to UK£14.00Up from UK£13.06, the current price target is an average from 12 analysts. The new target price is 18% below the current share price of UK£17.04. As of last close, the stock is up 22% over the past year.
分析記事 • Jun 24Abcam plc (LON:ABC) Shares Could Be 28% Below Their Intrinsic Value EstimateIn this article we are going to estimate the intrinsic value of Abcam plc ( LON:ABC ) by projecting its future cash...
分析記事 • May 01Is Abcam (LON:ABC) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Buying Opportunity • Apr 21Now 22% undervaluedOver the last 90 days, the stock is up 4.2%. The fair value is estimated to be UK£17.08, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.7% over the last 3 years. Meanwhile, the company has become profitable. For the next 3 years, revenue is forecast to grow by 12% per annum. Earnings is also forecast to grow by 35% per annum over the same time period.
Recent Insider Transactions • Apr 09Key Executive recently bought UK£67k worth of stockOn the 4th of April, Peter Allen bought around 5k shares on-market at roughly UK£14.36 per share. This was the largest purchase by an insider in the last 3 months. This was Peter's only on-market trade for the last 12 months.
Major Estimate Revision • Mar 21Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 EPS estimate fell from UK£0.20 to UK£0.16 per share. Revenue forecast steady at UK£378.0m. Net income forecast to grow 708% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target down from UK£15.70 to UK£15.27. Share price rose 8.4% to UK£13.59 over the past week.
Reported Earnings • Mar 15Full year 2021 earnings: EPS misses analyst expectationsFull year 2021 results: EPS: UK£0.019 (up from UK£0.009 loss in FY 2020). Revenue: UK£315.4m (up 17% from FY 2020). Net income: UK£4.40m (up UK£6.30m from FY 2020). Profit margin: 1.4% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 66%. Over the next year, revenue is forecast to grow 19%, compared to a 20% growth forecast for the pharmaceuticals industry in the United Kingdom. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 80 percentage points per year, which is a significant difference in performance.
Major Estimate Revision • Mar 08Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.07 to UK£0.06 per share. Revenue forecast steady at UK£313.9m. Net income forecast to grow 75% next year vs 23% growth forecast for Biotechs industry in the United Kingdom. Consensus price target of UK£15.71 unchanged from last update. Share price fell 4.9% to UK£11.71 over the past week.
分析記事 • Mar 08Is There An Opportunity With Abcam plc's (LON:ABC) 39% Undervaluation?Today we will run through one way of estimating the intrinsic value of Abcam plc ( LON:ABC ) by estimating the...
Major Estimate Revision • Jan 07Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 EPS estimate fell from UK£0.10 to UK£0.09 per share. Revenue forecast steady at UK£317.0m. Net income forecast to grow 147% next year vs 7.0% growth forecast for Biotechs industry in the United Kingdom. Consensus price target up from UK£14.89 to UK£15.21. Share price fell 12% to UK£15.28 over the past week.
分析記事 • Nov 22Calculating The Fair Value Of Abcam plc (LON:ABC)Does the November share price for Abcam plc ( LON:ABC ) reflect what it's really worth? Today, we will estimate the...
Recent Insider Transactions Derivative • Nov 12CEO & Executive Director exercised options and sold UK£926k worth of stockOn the 8th of November, Alan Hirzel exercised options to acquire 55k shares at no cost and sold these for an average price of UK£16.89 per share. This trade did not impact their existing holding. For the year to June 2020, Alan's total compensation was 39% salary and 61% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2021, Alan's direct individual holding has increased from 214.87k shares to 221.76k. Company insiders have collectively sold UK£1.1m more than they bought, via options and on-market transactions in the last 12 months.
Recent Insider Transactions • Sep 26CEO & Executive Director recently sold UK£94k worth of stockOn the 23rd of September, Alan Hirzel sold around 6k shares on-market at roughly UK£15.36 per share. This was the largest sale by an insider in the last 3 months. This was Alan's only on-market trade for the last 12 months.
Reported Earnings • Sep 15Full year 2021 earnings released: EPS UK£0.073 (vs UK£0.06 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: UK£297.7m (up 14% from FY 2020). Net income: UK£16.2m (up 30% from FY 2020). Profit margin: 5.4% (up from 4.8% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
Director Overboarding • Aug 04Director Mara Aspinall has joined 5th company boardIndependent Non-Executive Director Mara Aspinall has been appointed to the board of DA32 Life Science Tech Acquisition Corp. (NasdaqCM:DALS). Aspinall now sits on a total of 5 company boards. According to the Simply Wall St Risk Model, the director is at risk of having too many board obligations.
分析記事 • Jun 25Shareholders Will Probably Be Cautious Of Increasing Abcam plc's (LON:ABC) CEO Compensation At The MomentThe anaemic share price growth at Abcam plc ( LON:ABC ) over the past few years has probably not impressed shareholders...
Executive Departure • May 27Senior Independent Director has left the companyOn the 19th of May, Louise A. V. Patten's tenure as Senior Independent Director ended after 6.5 years in the role. As of March 2021, Louise A. V. personally held 54.84k shares (UK£763k worth at the time). Louise A. V. is the only executive to leave the company over the last 12 months.
Reported Earnings • Mar 10First half 2021 earnings released: EPS UK£0.053 (vs UK£0.13 in 1H 2020)The company reported a soft first half result with weaker earnings and profit margins, although revenues improved. First half 2021 results: Revenue: UK£147.5m (up 6.7% from 1H 2020). Net income: UK£11.7m (down 55% from 1H 2020). Profit margin: 7.9% (down from 19% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings.
Analyst Estimate Surprise Post Earnings • Mar 09Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 1.3%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%. Over the next year, revenue is forecast to grow 18%, compared to a 44% growth forecast for the Biotechs industry in the United Kingdom.
Price Target Changed • Feb 22Price target raised to UK£14.14Up from UK£13.09, the current price target is an average from 12 analysts. The new target price is 16% below the current share price of UK£16.76. As of last close, the stock is up 37% over the past year.
分析記事 • Feb 09Here's What We Think About Abcam's (LON:ABC) CEO PayAlan Hirzel has been the CEO of Abcam plc ( LON:ABC ) since 2014, and this article will examine the executive's...
Recent Insider Transactions Derivative • Feb 06CFO & Director exercised options and sold UK£73k worth of stockOn the 3rd of February, Michael Baldock exercised options to acquire 4k shares at no cost and sold these for an average price of UK£16.40 per share. This trade did not impact their existing holding. As of today, Michael currently holds no shares directly. Company insiders have collectively sold UK£260k more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Jan 19Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate increased from UK£0.11 to UK£0.13. Revenue estimate for the same period was approximately flat at UK£298.0m. Net income is expected to grow by 139% next year compared to 4.2% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£13.09 to UK£14.00. Share price is up 2.8% to UK£17.13 over the past week.
分析記事 • Jan 17Abcam plc's (LON:ABC) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?Most readers would already be aware that Abcam's (LON:ABC) stock increased significantly by 30% over the past three...
Price Target Changed • Jan 15Price target raised to UK£14.00Up from UK£13.06, the current price target is an average from 12 analysts. The new target price is 18% below the current share price of UK£17.04. As of last close, the stock is up 22% over the past year.
Is New 90 Day High Low • Jan 13New 90-day high: UK£16.66The company is up 29% from its price of UK£12.92 on 14 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£7.26 per share.
分析記事 • Dec 27Shareholders Are Thrilled That The Abcam (LON:ABC) Share Price Increased 124%When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...
Major Estimate Revision • Dec 19Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate was lowered from UK£0.14 to UK£0.11. No change was made to the revenue estimate which at the last update was UK£297.2m. Net income is expected to grow by 94% next year compared to 4.1% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£12.65 to UK£12.96. Share price is up 1.6% to UK£14.38 over the past week.
分析記事 • Dec 06Are Abcam's (LON:ABC) Statutory Earnings A Good Reflection Of Its Earnings Potential?It might be old fashioned, but we really like to invest in companies that make a profit, each and every year. However...
Recent Insider Transactions Derivative • Nov 05CEO & Executive Director exercised options and sold UK£291k worth of stockOn the 3rd of November, Alan Hirzel exercised options to acquire 19.43k shares at no cost and sold these for an average price of UK£14.99 per share. This trade did not impact their existing holding. For the year to June 2020, Alan's total compensation was 39% salary and 61% non-salary (Indicating these sales could comprise a meaningful part of their income for the year). Since December 2019, Alan's direct individual holding has increased from 151.13k shares to 180.26k. Company insiders have collectively sold UK£16m more than they bought, via options and on-market transactions in the last 12 months.
Major Estimate Revision • Oct 24Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate was lowered from UK£0.14 to UK£0.13. Revenue estimate was approximately flat at UK£296.9m. Net income is expected to grow by 123% next year compared to 11% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target was lowered from UK£12.67 to UK£12.37. Share price is up 9.6% to UK£14.41 over the past week.
Is New 90 Day High Low • Oct 22New 90-day high: UK£14.25The company is up 8.0% from its price of UK£13.21 on 24 July 2020. The British market is down 5.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£5.10 per share.
Major Estimate Revision • Oct 09Analysts update estimatesThe 2021 consensus earning per share (EPS) estimate was lowered from UK£0.16 to UK£0.14. Revenue estimate was approximately flat at UK£298.3m. Net income is expected to grow by 145% next year compared to 9.5% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target was lowered from UK£12.84 to UK£12.67. Share price stayed mostly flat at UK£12.13 over the past week.
Reported Earnings • Oct 04Full year earnings released - EPS UK£0.06Over the last 12 months the company has reported total profits of UK£12.5m, down 72% from the prior year. Total revenue was UK£260.0m over the last 12 months, largely unchanged from the prior year. Profit margins were 4.8%, which is lower than the 17% margin from last year. The decrease in margin was driven by higher expenses.
Major Estimate Revision • Sep 21Analysts update estimatesThe 2021 consensus revenue estimate increased from UK£298.3m to UK£301.4m. Earnings per share (EPS) estimate was lowered from UK£0.19 to UK£0.15 for the same period. Net income is expected to grow by 161% next year compared to 12% growth forecast for the Biotechs industry in the United Kingdom. The consensus price target increased from UK£12.62 to UK£12.89. Share price is down by 9.9% to UK£12.45 over the past week.